On Wednesday, Shares of Apple Inc. (NASDAQ:AAPL), surged 4.29% to $112.34.
Japan Display Inc Chief Executive Mitsuru Homma on Thursday said the screen maker’s “biggest client”, widely understood to refer to Apple Inc , is increasing orders ahead of the predictable launch of a new iPhone this month, according to Reuters.
Homma said weakness in China’s smartphone market, the world’s biggest, amid that country’s broader economic slowdown did not appear to be affecting Apple’s screen orders.
“They’re coming to us with more orders, saying ‘give us more, give us more’. They keep increasing,” he told Reuters in an interview. Reuters Reports
Apple Chief Executive Tim Cook last week reassured shareholders about the strength of the Chinese market for iPhones after a slump in China’s stock market and the devaluation of the yuan rattled investors. Reuters added.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), declined -16.99% to $7.55, during its last trading session.
Baxalta Inc., the drugmaker fending off a $30 billion takeover offer from Shire Plc, has abandoned its pursuit of Ariad Pharmaceuticals Inc. after negotiations broke down over price, people with knowledge of the matter said. Bloomberg Reports
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with 5.36% gain, and closed at $5.90.
Exelixis declared that data from clinical trials of cabozantinib and cobimetinib will be the subject of three presentations at the European Cancer Congress (ECC) 2015, which will be held September 25-29, 2015, in Vienna, Austria.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
